The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alternative trastuzumab dosing schedules and association with health care greenhouse gas emissions.
 
Garth William Strohbehn
Consulting or Advisory Role - Vivio Health
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a filed patent held by the University of Chicago covering the use of low-dose tocilizumab in the treatment of viral infections. (Inst); Co-inventor of a method-of-use patent filed by the U.S. Department of Veterans Affairs and held by U.S. Department of Veterans Affairs and University of Michigan covering methods, systems, and apparatuses for post-approval dose optimization. (Inst)
(OPTIONAL) Uncompensated Relationships - Optimal Cancer Care Alliance (OCCA); U.S. Department of Veterans Affairs
 
Sofia Jacobson
Employment - Kaia Health (I)
Leadership - Kaia Health (I)
(OPTIONAL) Uncompensated Relationships - Optimal Cancer Care Alliance (OCCA) (I)
 
Alec Kacew
No Relationships to Disclose
 
Randall W. Knoebel
No Relationships to Disclose
 
Po-Hung Hsieh
No Relationships to Disclose
 
Mark J. Ratain
Stock and Other Ownership Interests - SAB Biotherapeutics; SAB Biotherapeutics
Honoraria - Emerson Lake Safety
Consulting or Advisory Role - Apotex; Aptevo Therapeutics; Arvinas; Ayala Pharmaceuticals; Bayer; Bluebird Bio; Cantex Pharmaceuticals; Eagle Pharmaceuticals; EMD Serono; EQRx; Genentech; Oncovalent Therapeutics
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Genentech/Roche (Inst); Incyte (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Provisional patent application for method of treating viral pneumonitis with low-dose tocilizumab (Inst); royalties related to UGT1A1 genotyping for irinotecan; royalties related to UGT1A1 genotyping for irinotecan (Inst)
Expert Testimony - Multiple generic companies (defendants in patent litigation)
Other Relationship - Credit Suisse; Optimal Cancer Care Alliance (OCCA); William Blair